PCM
ABUS icon

Penserra Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Penserra Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,265
Closed -$9K – 1344
2021
Q3 		$9K Buy
2,265
+70
+3% +$233 ﹤0.01% 1364
2021
Q2 		$6K Buy
2,195
+255
+13% +$790 ﹤0.01% 1307
2021
Q1 		$6K Sell
1,940
-10
-0.5% -$39 ﹤0.01% 1071
2020
Q4 		$6K Buy
+1,950
New +$6.83K ﹤0.01% 966

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

Penserra Capital Management's ABUS Position: Q4 2021 in Review

Penserra Capital Management sold out of Arbutus Biopharma (ABUS) in Q4 2021, closing a stake of 2,265 shares — an estimated $9K sold.

Penserra Capital Management first reported a position in ABUS in Q4 2020 and held it in 4 quarters. The position peaked at $9K in Q3 2021. 122 funds tracked by Wall St. Rank hold ABUS as of Q4 2021.

  • Penserra Capital Management reported no remaining Arbutus Biopharma position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 2,265 Arbutus Biopharma shares in Q4 2021, an estimated $9K.
  • Penserra Capital Management first reported a position in Arbutus Biopharma in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Arbutus Biopharma position peaked at $9K in Q3 2021.
  • 122 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.